Verastem stock to present updated VS-7375 lung data on Dec. 5
Published on 11/19/2026 at 13:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline Milestones Ahead
- Verastem will present updated Phase 1/2 TARGET-D 101 data for previously treated KRAS G12D-mutated metastatic non-small cell lung cancer on December 5.
- A separate trial-in-progress abstract will cover the Phase 2 TARGET-D 202 lung-cancer study.
- The company is developing VS-7375 across pancreatic, lung and colorectal cancers.
On November 18, 2026, Verastem Oncology announced that updated clinical data for its investigational KRAS G12D inhibitor VS-7375 had been selected for an oral presentation at the IASLC/ASCO 2026 North America Conference on Lung Cancer. The announcement was carried by BioSpace from a Business Wire release.
Data Presentation Set For December
The late-breaking oral presentation will cover updated Phase 1/2 TARGET-D 101 results in previously treated patients with KRAS G12D-mutated metastatic non-small cell lung cancer. The session is scheduled for Saturday, December 5, from 2:45 to 4:15 p.m. Mountain Standard Time, with Marcelo V. Negrao of MD Anderson Cancer Center as presenter.
A separate trial-in-progress abstract for TARGET-D 202, Verastem's registration-directed Phase 2 study in advanced non-small cell lung cancer, has been accepted for a poster presentation on December 5 from 4:15 to 5:45 p.m. Mountain Standard Time.
Broader Development Program
Verastem said the updated TARGET-D 101 findings build on October results that included confirmed responses in previously treated non-small cell lung cancer, including patients who had received taxanes. The company is positioning VS-7375 as an oral, selective inhibitor designed to bind both active and inactive forms of KRAS G12D.
The company is also enrolling patients in Phase 2 studies covering pancreatic cancer, non-small cell lung cancer and colorectal cancer. Verastem said no therapy specifically targeting KRAS G12D has been approved by the U.S. Food and Drug Administration.
Verastem stock traded at 6.22 euros on Lang & Schwarz at 13:48 CET on Thursday, November 19, 2026.
Verastem Oncology
- ISIN: US92337C2035
- Ticker: VSTM
- Primary exchange: Nasdaq
- Lang & Schwarz quote: 6.22 euros at 13:48 CET on November 19, 2026
The broader U.S. market backdrop is covered in current S&P 500 market reports.
